TABLE A1.
Baseline Characteristics of the mUC-EV Cohort
| Characteristic | Nonamplified (n = 80) | Amplified (n = 28) | P a |
|---|---|---|---|
| Sex, No. (%) | .043 | ||
| Male | 56 (70) | 25 (89) | |
| Female | 24 (30) | 3 (11) | |
| Age, years | .2 | ||
| Median (IQR) | 68, (58-73) | 69, (61-75) | |
| Range | 33-89 | 55-89 | |
| ECOG, No. (%) | .9 | ||
| 0 | 26 (33) | 10 (36) | |
| 1 | 43 (54) | 14 (50) | |
| ≥2 | 10 (13) | 4 (14) | |
| Hemoglobin, g/dL, No. (%) | .6 | ||
| ≥10 | 76 (95) | 28 (100) | |
| <10 | 4 (5.0) | 0 (0) | |
| Liver metastases, No. (%) | .011 | ||
| No | 51 (64) | 25 (89) | |
| Yes | 29 (36) | 3 (11) |
NOTE. Significant P values are highlighted in bold.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; mUC-EV, metastatic urothelial cancer-enfortumab vedotin.
a
Pearson's chi-squared test; Wilcoxon rank-sum test; Fisher's exact test.